huC242-DM4 Treating Patients With Metastatic Gastric or Gastroesophageal Junction Carcinomas
To assess the response rate of huC242-DM4 given as an intravenous infusion to patients with metastatic or locally advanced gastric or gastroesophageal junction cancer.
Stomach Neoplasms|Metastatic or Locally Advanced Gastric Cancer|Metastatic or Local Advanced GE Junction Cancer
DRUG: huC242-DM4
response rate, year
duration of response, as necessary|progression free survival, as necessary|safety and tolerability, while on study|Pharmacokinetic (PK) assessment, while on study|effect of huC242-DM4 on tumor uptake of FDG, while on study
To assess the response rate of huC242-DM4 given as an intravenous infusion to patients with metastatic or locally advanced gastric or gastroesophageal junction cancer.